FibroGen Inc (NASDAQ:FGEN) was the recipient of unusually large options trading on Monday. Stock traders acquired 7,459 call options on the company. This represents an increase of 3,574% compared to the typical volume of 203 call options.
In other news, CEO Thomas B. Neff sold 18,900 shares of the stock in a transaction on Thursday, October 18th. The stock was sold at an average price of $54.52, for a total transaction of $1,030,428.00. Following the completion of the sale, the chief executive officer now owns 2,710,412 shares in the company, valued at approximately $147,771,662.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Pat Cotroneo sold 1,011 shares of the stock in a transaction on Monday, September 10th. The shares were sold at an average price of $57.35, for a total value of $57,980.85. Following the sale, the senior vice president now owns 220,422 shares of the company’s stock, valued at approximately $12,641,201.70. The disclosure for this sale can be found here. Insiders sold 236,673 shares of company stock valued at $14,005,902 over the last 90 days. 8.96% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in shares of FibroGen by 360.0% in the third quarter. Russell Investments Group Ltd. now owns 31,169 shares of the biopharmaceutical company’s stock valued at $1,894,000 after purchasing an additional 24,393 shares in the last quarter. Alps Advisors Inc. lifted its holdings in shares of FibroGen by 23.7% in the third quarter. Alps Advisors Inc. now owns 149,236 shares of the biopharmaceutical company’s stock valued at $9,066,000 after purchasing an additional 28,570 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of FibroGen by 37.8% in the third quarter. First Trust Advisors LP now owns 1,652,213 shares of the biopharmaceutical company’s stock valued at $100,372,000 after purchasing an additional 453,288 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in shares of FibroGen by 10.5% in the third quarter. Handelsbanken Fonder AB now owns 190,000 shares of the biopharmaceutical company’s stock valued at $11,542,000 after purchasing an additional 18,000 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of FibroGen by 1,829.4% in the third quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 5,854 shares in the last quarter. Institutional investors own 76.09% of the company’s stock.
Shares of NASDAQ:FGEN opened at $41.62 on Tuesday. FibroGen has a one year low of $40.74 and a one year high of $68.55. The firm has a market cap of $3.95 billion, a PE ratio of -24.06 and a beta of 1.81. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.95 and a quick ratio of 7.95.
FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.31. The company had revenue of $43.95 million during the quarter, compared to analyst estimates of $28.70 million. FibroGen had a negative return on equity of 22.60% and a negative net margin of 85.59%. On average, equities research analysts expect that FibroGen will post -1.05 EPS for the current year.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Further Reading: Marijuana Stocks Future Looks Bright
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.